The Primary Aim is to Compare the Outcomes of Autogenous Dentin Graft (ADG) Combined with Either Albumin Platelet-rich Fibrin (ALB-PRF) or Standard Platelet-rich Fibrin (PRF) in Terms of Bone Preservation and Healing in the Alveolar Socket.
Launched by KAFRELSHEIKH UNIVERSITY · Dec 26, 2024
Trial Information
Current as of July 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how different treatments can help preserve and heal bone after a tooth is removed. When a tooth is lost, the bone around it can shrink significantly, especially in the first few months. To prevent this, the study will compare two methods using a special type of graft made from the patient's own tooth material, called autogenous dentin, combined with either a standard treatment or a new treatment that uses a healing membrane made from the patient’s blood and albumin. The aim is to see which method better supports bone healing and prepares the area for future dental work.
To participate in this study, patients must be between 18 and 60 years old and need to have a tooth that can’t be saved, specifically in the back of the mouth. They should not have any serious health conditions or habits, like smoking, that could affect healing. Participants can expect to have their tooth extracted and then receive one of the treatments being studied. This trial is not yet open for recruiting, but it aims to improve recovery after tooth extractions and help maintain healthy bone structure for future dental needs.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Medically free patients.
- • Adult patients above 18 Years to 60 Years.
- • Non-restorable tooth indicated for extraction.
- • Posterior mandibular teeth.
- • Inactive infection related to the tooth.
- • Cooperative patients.
- Exclusion Criteria:
- • Presence of any systemic disease that could influence the outcome of the therapy.
- • Presence of any risk factor (smoker, pregnant and lactating patients).
- • Patients with bone diseases.
- • Patients with poor oral hygiene.
About Kafrelsheikh University
Kafrelsheikh University, a prominent academic institution located in Egypt, is dedicated to advancing medical research and clinical trials that contribute to the enhancement of healthcare practices and patient outcomes. With a strong emphasis on interdisciplinary collaboration, the university harnesses its diverse expertise in medical sciences, engineering, and technology to conduct rigorous clinical studies. Kafrelsheikh University aims to foster innovation in clinical research, ensuring compliance with ethical standards and regulatory requirements, while actively engaging in community health initiatives to address pressing health challenges. Through its commitment to excellence, the university seeks to develop evidence-based solutions that improve health and well-being at both local and global levels.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kafr El Sheikh, , Egypt
Patients applied
Trial Officials
Enas Ahmed Elgendy, PhD
Study Director
Kaferelsheikh University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported